Skip to main content

Table 1 Treatment doses for single and combined treatment. Eight UCCs, two immortalized benign urothelial cells (TERT-NHUC, HBLAK), primary urothelial cells (NHUC), and HEK-293 cells were treated with JQ1 at a fixed range of concentrations. Cell viability was measured by MTT- assay 72 h later. IC50 values for each cell line were determined (upper part). Cell viability results were used according to the Chou-Talalay method to determine doses for the combination treatment with synergistic effects for each investigated cell line. The respective doses were applied for further functional characterization for 48 h (lower part)

From: Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines

Urothelial carcinoma cell lines

Control cell lines

 

JQ1 IC50 [μmol/l]

 

JQ1 IC50 [μmol/l]

VM-Cub1

0.18

TERT-NHUC

0.4

RT-112

0.19

HBLAK

0.4

T24

0.23

NHUC

0.26

5637

0.39

HEK-293

0.26

UM-UC-3

2.6

  

HT-1376

5.2

  

639-V

6.8

  

BFTC-905

10

  

JQ1 + Romidepsin combination doses

 

JQ1 [μmol/l]

Romidepsin [nmol/l]

Vm-Cub1

0.22

2.2

UM-UC-3

1

2

T24

0.22

2.2

639-V

1.8

1.6

HBLAK

0.4

0.89